Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Prevention |
RCV000250189 | SCV000313381 | benign | not specified | criteria provided, single submitter | clinical testing | ||
Center for Pediatric Genomic Medicine, |
RCV000514745 | SCV000609673 | likely benign | not provided | 2017-05-24 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000514745 | SCV001890441 | benign | not provided | 2019-07-19 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000514745 | SCV002545409 | benign | not provided | 2023-09-01 | criteria provided, single submitter | clinical testing | TNXB: BP4, BS1, BS2 |
Genome Diagnostics Laboratory, |
RCV002278198 | SCV002566308 | benign | Ehlers-Danlos syndrome | 2022-02-08 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002365267 | SCV002665093 | benign | Cardiovascular phenotype | 2019-02-12 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Breakthrough Genomics, |
RCV000514745 | SCV005225622 | likely benign | not provided | criteria provided, single submitter | not provided |